is diarrhea a symptom of glp 1 on GLP-1 common, predictable, and manageable. Here's what's driving it and what to do about it. #obesitymedicine #womenshealth #obesitydoctor​​​​​​​​​​​​​​​​ Managing GLP-1/GIP side effects with

Future Prescr

Liraglutide exemplifies this approach through specific molecular modifications

Bristol-Myers Squibb (BMS) Total Revenue: $48.19B Founded Year: 1887 Total Employees: 32,500 Headquarters: New Jersey, United States Market Cap: $121.42B Stock Exchange: NYSE BMS is a global biopharma company focused on oncology, hematology, immunology, and cardiovascular diseases, with a strong portfolio of innovative therapies and a legacy of blockbuster drugs

Recent Developments: Initiated Phase 3 trials for orforglipron, aiming to provide an oral alternative to injectable GLP-1 drugs

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Really proud of the devices my teams at Lilly and Sanofi created and developed for 3 of these top products (Mounjaro, Dupixent, Zepbound)